513 related articles for article (PubMed ID: 21035406)
1. CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation.
Rakhra K; Bachireddy P; Zabuawala T; Zeiser R; Xu L; Kopelman A; Fan AC; Yang Q; Braunstein L; Crosby E; Ryeom S; Felsher DW
Cancer Cell; 2010 Nov; 18(5):485-98. PubMed ID: 21035406
[TBL] [Abstract][Full Text] [Related]
2. Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs.
Bellovin DI; Das B; Felsher DW
Adv Exp Med Biol; 2013; 734():91-107. PubMed ID: 23143977
[TBL] [Abstract][Full Text] [Related]
3. p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia.
Yetil A; Anchang B; Gouw AM; Adam SJ; Zabuawala T; Parameswaran R; van Riggelen J; Plevritis S; Felsher DW
Oncotarget; 2015 Feb; 6(6):3563-77. PubMed ID: 25784651
[TBL] [Abstract][Full Text] [Related]
4. BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia.
Li Y; Deutzmann A; Choi PS; Fan AC; Felsher DW
Oncotarget; 2016 May; 7(19):26926-34. PubMed ID: 27095570
[TBL] [Abstract][Full Text] [Related]
5. Immunology in the clinic review series; focus on cancer: multiple roles for the immune system in oncogene addiction.
Bachireddy P; Rakhra K; Felsher DW
Clin Exp Immunol; 2012 Feb; 167(2):188-94. PubMed ID: 22235994
[TBL] [Abstract][Full Text] [Related]
6. An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.
Casey SC; Li Y; Felsher DW
Immunol Res; 2014 May; 58(2-3):282-91. PubMed ID: 24791942
[TBL] [Abstract][Full Text] [Related]
7. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch.
Giuriato S; Ryeom S; Fan AC; Bachireddy P; Lynch RC; Rioth MJ; van Riggelen J; Kopelman AM; Passegué E; Tang F; Folkman J; Felsher DW
Proc Natl Acad Sci U S A; 2006 Oct; 103(44):16266-71. PubMed ID: 17056717
[TBL] [Abstract][Full Text] [Related]
8. Is oncogene addiction angiogenesis-dependent?
Folkman J; Ryeom S
Cold Spring Harb Symp Quant Biol; 2005; 70():389-97. PubMed ID: 16869776
[TBL] [Abstract][Full Text] [Related]
9. Noncanonical roles of the immune system in eliciting oncogene addiction.
Casey SC; Bellovin DI; Felsher DW
Curr Opin Immunol; 2013 Apr; 25(2):246-58. PubMed ID: 23571026
[TBL] [Abstract][Full Text] [Related]
10. Tumor dormancy and oncogene addiction.
Felsher DW
APMIS; 2008; 116(7-8):629-37. PubMed ID: 18834407
[TBL] [Abstract][Full Text] [Related]
11. MYC activation is a hallmark of cancer initiation and maintenance.
Gabay M; Li Y; Felsher DW
Cold Spring Harb Perspect Med; 2014 Jun; 4(6):. PubMed ID: 24890832
[TBL] [Abstract][Full Text] [Related]
12. Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit?
Felsher DW
Cancer Res; 2008 May; 68(9):3081-6; discussion 3086. PubMed ID: 18451131
[TBL] [Abstract][Full Text] [Related]
13. MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms.
Felsher DW
Genes Cancer; 2010 Jun; 1(6):597-604. PubMed ID: 21037952
[TBL] [Abstract][Full Text] [Related]
14. Oncogene withdrawal engages the immune system to induce sustained cancer regression.
Casey SC; Li Y; Fan AC; Felsher DW
J Immunother Cancer; 2014; 2():24. PubMed ID: 25089198
[TBL] [Abstract][Full Text] [Related]
15. Survival and death signals can predict tumor response to therapy after oncogene inactivation.
Tran PT; Bendapudi PK; Lin HJ; Choi P; Koh S; Chen J; Horng G; Hughes NP; Schwartz LH; Miller VA; Kawashima T; Kitamura T; Paik D; Felsher DW
Sci Transl Med; 2011 Oct; 3(103):103ra99. PubMed ID: 21974937
[TBL] [Abstract][Full Text] [Related]
16. In vivo imaging-based mathematical modeling techniques that enhance the understanding of oncogene addiction in relation to tumor growth.
Nwabugwu C; Rakhra K; Felsher D; Paik D
Comput Math Methods Med; 2013; 2013():802512. PubMed ID: 23573174
[TBL] [Abstract][Full Text] [Related]
17. Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway.
Wang X; Yang J; Guo G; Feng R; Chen K; Liao Y; Zhang L; Sun L; Huang S; Chen JL
Mol Cancer; 2019 Apr; 18(1):84. PubMed ID: 30961617
[TBL] [Abstract][Full Text] [Related]
18. Expression of lymphomagenic oncogenes in T-cell lymphomas of HPV 16 transgenic mice.
Yang JT; Liu CZ; Domer P; Iannaccone P
Cancer Detect Prev; 1998; 22(5):405-15. PubMed ID: 9727621
[TBL] [Abstract][Full Text] [Related]
19. Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas.
Tran PT; Fan AC; Bendapudi PK; Koh S; Komatsubara K; Chen J; Horng G; Bellovin DI; Giuriato S; Wang CS; Whitsett JA; Felsher DW
PLoS One; 2008 May; 3(5):e2125. PubMed ID: 18461184
[TBL] [Abstract][Full Text] [Related]
20. The MYC oncogene is a global regulator of the immune response.
Casey SC; Baylot V; Felsher DW
Blood; 2018 May; 131(18):2007-2015. PubMed ID: 29514782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
